PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
Recruitment status was: Recruiting
|Study Design:||Time Perspective: Retrospective|
|Study Start Date:||September 2007|
Patients chronically treated with drug losartan
Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
Patients not chronically treated with losartan
The losartan metabolite EXP3179 potently induces the activity of the peroxisome proliferator-activated receptor γ (PPAR-γ) as a partial agonist in vitro. PPAR-γ is a nuclear hormone receptor and functions as a regulator of lipid- and glucose metabolism. PPAR-γ ligands improve insulin sensitivity and glucose tolerance, and reduce cardiovascular morbidity and mortality in diabetic patients.
Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites in patients would markedly improve the pharmacological profile of losartan by combining anti-hypertensive and highly beneficial metabolic actions. We developed the following hypothesis:
- Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels of EXP3179 to activate PPARγ.
- PPARγ target genes are induced in monocytes from losartan-treated patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00561327
|Contact: Eckart Fleck, Proffirstname.lastname@example.org|
|Contact: Philipp Stawowy, Dremail@example.com|
|German Heart Institute||Recruiting|
|Berlin, Germany, 13353|
|Contact: Eckart Fleck, Prof +49-30-4593 2400 firstname.lastname@example.org|
|Contact: Philipp Stawowy, Dr +49-30-45932473 email@example.com|
|Principal Investigator: Eckart Fleck, Prof|
|Principal Investigator:||Eckart Fleck, Prof||German Heart Institute|
|Principal Investigator:||Ulrich Kintscher, Prof||Institute of Pharmacology Charite University Medicine Berlin Germany|